Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: An in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 9, 1997, Pages 1880-1887

  Pettoello Mantovani, Massimo ^a   Kollmann, Tobias R ^a   Raker, Christina ^a   Kim, Ana ^a   Yurasov, Sergey ^a   Tudor, Robert ^b   Wiltshire, Hugh ^c   Goldstein, Harris ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; SAQUINAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FETAL TISSUE TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER; LYMPHOID TISSUE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCID MOUSE; SPLEEN; THYMUS; VIRUS REPLICATION;

EID: 0030875915     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.9.1880     Document Type: Article

References (34)

1. AIDS Clinical Trials Group, A. C. Collier, R. W. Coombs, D. A. Schoenfeld et al. 1995. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 333:1528-1533.
2. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
3. Cohen, J., and E. Pennisi. 1996. Eradicating HIV from a patient: not just a dream. Science 272:1884.
4. Condra, J. H., W. A. Schleif, P. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
5. Craig, J. C., I. B. Duncan, D. Hockley, C. Grief, N. A. Roberts, and J. S. Mills. 1991. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res. 16:295-305.
6. Eberle, J., B. Bechowsky, D. Rose, U. Hauser, K. von der Helm, L. Gurtler, and H. Nitschko. 1995. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959. AIDS Res. Hum. Retroviruses 11:671-676.
7. Embretson, J., M. Zupanic, J. L. Ribas, A. Burke, P. Racz, K. Tenner-Racz, and A. T. Haase. 1993. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Science 362: 359-362.
8. European-Australian Collaborative Ritonavir Study Group, S. A. Danner, A. Carr, J. M. Leonard et al. 1995. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333:1528-1533.
9. Ezzel, C. 1996. Emergence of the protease inhibitors: a better class of AIDS drugs? J. NIH Res. 8:41-45.
10. Fauci, A. 1993. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 262:1011-1018.
11. Ho, D. D., T. Moudgil, and M. Alum. 1989. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N. Engl. J. Med. 321:1621-1625.
12. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
13. Jacobsen, H., K. Yasargil, D. L. Winslow, J. C. Craig, A. Krohn, I. B. Duncan, and J. Mous. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206:527-534.
14. Kitchen, V. S., C. Skinner, K. Ariyoshi, E. A. Lane, I. B. Duncan, J. Burckhardt, H. U. Burger, K. Bragman, and A. J. Pinching. 1995. Safety and activity of saquinavir in HIV infection. Lancet 345:952-955.
15. Kollmann, T. R., X. Zhuang, A. Rubinstein, and H. Goldstein. 1992. Design of polymerase chain reaction primers for the selective amplification of HIV-1 RNA in the presence of HIV-1 DNA. AIDS 6:547-552.
16. Kollmann, T. R., M. Pettoello-Mantovani, X. Zhuang, A. Kim, M. Hachamovitch, P. Smarnworawong, A. Rubinstein, and H. Goldstein. 1994. Disseminated HIV-1 infection in SCID-hu mice after peripheral inoculation with HIV-1. J. Exp. Med. 179:513-522.
17. Kollmann, T. R., A. Kim, M. Pettoello-Mantovani, M. Hachamovitch, A. Rubinstein, M. M. Goldstein, and H. Goldstein. 1995. Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice. J. Immunol. 154:907-921.
18. Kollmann, T. R., M. Pettoello-Mantovani, N. Katopodis, A. Rubinstein, A. Kim, M. Hachamovitch, and H. Goldstein. 1996. Demonstration of in vivo inhibition of HIV infection by treatment of SCID-hu mice with IL-10. Proc. Natl. Acad. Sci. USA 93:3126-3131.
19. Krone, W. J. A., J. J. Sninsky, and J. Goudsmit. 1990. Detection and characterization of HIV-1 by polymerase chain reaction. J. Acquired Immune Defic. Syndr. 3:517-524.
20. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, and F. Sattler. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333: 1534-1539.
21. McCune, J. M., R. Namikawa, C.-C. Shih, L. Rabin, and H. Kaneshima. 1990. Suppression of HIV infection in AZT-treated SCID-hu mice. Science 247:564-566.
22. McCune, J. M. 1991. HIV-1: the infective process in vivo. Cell 64:351-363.
23. McCune, J. M., B. Peault, P. R. Streeter, and L. Rabin. 1991. Preclinical evaluation of human hematolymphoid function in the SCID-hu mouse. Immunol. Rev. 124:45-62.
24. Namikawa, R., H. Kaneshima, M. Lieberman, I. L. Weissman, and J. M. McCune. 1988. Infection of the SCID-hu mouse by HIV-1. Science 242: 1684-1686.
25. Pantaleo, G., C. Graziosi, L. Butini, P. A. Pizzo, S. M. Schnittman, D. P. Kotler, and A. S. Fauci. 1991. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 8:9838-9842.
26. Pantaleo, G., C. Graziosi, J. F. Demerest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenstein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Science 362:355-358.
27. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
28. Piatak, M., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K.-C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
29. Richman, D. D. 1996. HIV therapeutics. Science 272:1886-1888.
30. Ridkey, T., and J. Leis. 1995. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270:29621-29623.
31. Schapiro, J. M., M. A. Winters, F. Stewary, B. Efron, J. Morris, M. J. Kozal, and T. C. Merrigan. 1996. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann. Intern. Med. 124: 1039-1050.
32. Schnittman, S., J. J. Greenhouse, H. C. Lane, P. F. Pierce, and A. S. Fauci. 1991. Frequent detection of HIV-1 specific mRNAs in infected individuals suggests ongoing active viral replication in all stages of disease. AIDS Res. Hum. Retroviruses 7:361-366.
33. Vella, S. 1994. Update on a protease inhibitor. AIDS 8:525-529.
34. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.